About Us
Learn more about InSitu Biologics
InSitu Biologics
InSitu Biologics, LLC is an emerging biotech company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.
For Media & Press
Please contact
Katie M.
Katie@insitubiologics.com
For Investors
Please contact
Jim Segermark, CEO
Jim@insitubiologics.com
651-337-4799
Pre-Clinical Results
As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.
A Non-Opioid Surgical Analgesic
InSitu Biologics is an emerging drug delivery company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.
- 22+ US Patents Issued, with matching OUS positions
- Hydrogel technology licensed from Cleveland Clinic Foundation
- Tunable, biocompatible, and pH neutral platform
- High dose drug-load reservoir capacity with a predictable pharmacological effect
- Non-opioid pain relief option
Investment Opportunity
InSitu Biologics is hosting a Regulation A+ offering to a limited number of investors.
Why Invest
- Non-opioid painkiller – pre-clinical stage
- Lasts up to 300% longer than leading competitor*
- 22 U.S. Patents
- Invest with your IRA
The Offering
Competitor Market Size
Timeline
-
2016
Q1
Filed additional patent(s)Q2
White Paper publishedQ3
Completed maximum dosing study with no toxicityQ4
Presented at PODD-Boston
-
2017
Q1
Completed first GLP studyQ2
Proved more pain relief compared to Exparel in pre-clinical studyQ3
GLP publication acceptedQ4
Raised over $400k
-
2018
Q1
Completed Financial Audit
Converted all debt
Filed $10,000,000 RegA+ OfferingQ2
Launch RegA+ Offering
Announce GLP Paper by Hutchins & TaylorQ3
Begin Phase 1 program manufacturingQ4
Announce final GLP Study results -
2019
Q1
SEC valuation incorporating Animal Care Market opportunityQ2
Submit GLP results for Peer-ReviewQ3
FDA Pre-IND meetingQ4
Expect approval for Phase 1 Clinical Study of AnestaGel
Executive Team
James Segermark
CEOJim has been the founder, inventor, investor, and owner operator in many med-tech ventures. Jim began working on the Matrix technology in 2007 and co-founded InSitu Biologics in 2014. Jim is an inventor on over 40 issued patents for medical products, and specializes in the total enterprise of bringing proprietary products from “just an idea” through design, scaled up manufacturing, and “to the patient”. Jim earned his Bachelor of Science from Carroll University in Waukesha, Wisconsin and his MBA from Cardinal Stritch University in Milwaukee.
Bill Taylor
Chief ScientistBill is a Co-Founder of InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a successful medical product development programs manager and scientist, and has been awarded over $900k in government research grants, and authored industry papers in chemical remediation and demilitarization utilizing biological systems. Bill has his Bachelor of Science from the University of Minnesota with a double major in Chemical Engineering and Biology.